The phase 3 PANORAMA trial of Eylea in patients with moderately severe to severe nonproliferative diabetic retinopathy met its 24-week endpoint, according to a press release from Regeneron.
At week 24, 58% of patients treated with Eylea (aflibercept) injection experienced a two-step or greater improvement from baseline on the Diabetic Retinopathy Severity Scale compared with 6% of patients who received a sham injection (P < .0001), the release said.
“This is the first time a therapy has demonstrated it can reverse disease progression in patients with moderately severe to severe
Uncategorized